<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib30">
 <element-citation publication-type="journal" id="sref30">
  <person-group person-group-type="author">
   <name>
    <surname>Konno</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Kimura</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Uriu</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Fukushi</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Irie</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Koyanagi</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Nakagawa</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Sato</surname>
    <given-names>K.</given-names>
   </name>
  </person-group>
  <article-title>SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant</article-title>
  <source>bioRxiv</source>
  <year>2020</year>
  <comment>2020.05.11.088179</comment>
 </element-citation>
</ref>
